Last reviewed · How we verify
Cathflo Activase (Alteplase)
Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots.
Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots. Used for Restoration of function to central venous catheters occluded by thrombus.
At a glance
| Generic name | Cathflo Activase (Alteplase) |
|---|---|
| Sponsor | Genentech, Inc. |
| Drug class | Fibrinolytic agent / Tissue plasminogen activator (tPA) |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Interventional |
| Phase | FDA-approved |
Mechanism of action
Alteplase is a recombinant human tissue plasminogen activator that directly activates the fibrinolytic system by converting plasminogen to plasmin. Plasmin then degrades fibrin, the structural protein in blood clots, leading to clot dissolution. Cathflo Activase is specifically formulated for catheter-directed thrombolysis to restore patency of occluded central venous catheters.
Approved indications
- Restoration of function to central venous catheters occluded by thrombus
Common side effects
- Bleeding
- Sepsis
- Catheter-related infection
Key clinical trials
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion (EARLY_PHASE1)
- Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis (PHASE2)
- Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis (PHASE4)
- EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs (PHASE3)
- Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE (PHASE4)
- Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol (NA)
- Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure (PHASE2)
- TPA in Acute Stroke With COVID Verus Non-COVID-19 Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cathflo Activase (Alteplase) CI brief — competitive landscape report
- Cathflo Activase (Alteplase) updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI